GLPwatch
Response to: Letter to the Editor Regarding Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM.
Adv Ther · 2023
Last updated 2026-05-28| Journal | Adv Ther, 2023 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Full record and abstract on PubMed 36261771 ↗